Adventitial transduction of lentivirus-shRNA-VEGF-A in arteriovenous fistula reduces venous stenosis formation.
Binxia Yang, Rajiv Janardhanan, Pawan Vohra...
https://pubmed.ncbi.nlm.nih.gov/23924957/Actively Recruiting
Led by Suzhou Municipal Hospital · Updated on 2024-05-16
300
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are assessing the impact of a 12-week low-intensity pulsed ultrasound LIPUS treatment on the maturation of newly created autologous arteriovenous fistulas in patients with uremia. This prospective, blinded, randomized controlled trial is conducted in two stages an initial single-center concept validation followed by a larger multicenter key trial. The study aims to compare the maturation rate of fistulas between those receiving LIPUS and a control group, ensuring safety and efficacy are carefully evaluated throughout.
CONDITIONS
The Effect of LIPUS on the Maturation of Newly Constructed Autogenous AVF
Q
Qiang Chen
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Suzhou Municipal Hospital
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants receive low-intensity pulsed ultrasound (LIPUS) intervention at the arteriovenous fistula site starting no more than 3 days after suture removal, three times a week during dialysis sessions, each lasting 20 minutes, for a total treatment period of 12 weeks.
Three times a week during dialysis sessions
Duration - 4 weeks
Participants are monitored for changes in hemodynamic parameters and the maturity of the arteriovenous fistula after completing the treatment period.
1 visit 4 weeks after treatment completion
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Binxia Yang, Rajiv Janardhanan, Pawan Vohra...
https://pubmed.ncbi.nlm.nih.gov/23924957/Andrea Remuzzi, Michela Bozzetto, Paolo Brambilla
https://pubmed.ncbi.nlm.nih.gov/28297046/Eric J Charles, Yikui Tian, Aimee Zhang...
https://pubmed.ncbi.nlm.nih.gov/31839230/Tianhua Xu, Jia Gu, Chenghai Li...
https://pubmed.ncbi.nlm.nih.gov/29636884/Agnes Masengu, James McDaid, Alexander P Maxwell...
https://pubmed.ncbi.nlm.nih.gov/26804217/Joseph A Vassalotti, William C Jennings, Gerald A Beathard...
https://pubmed.ncbi.nlm.nih.gov/22487024/Mehmet Ali Kaygin, Umit Halici, Ahmet Aydin...
https://pubmed.ncbi.nlm.nih.gov/23906289/Ashley B Irish, Andrea K Viecelli, Carmel M Hawley...
https://pubmed.ncbi.nlm.nih.gov/28055065/Zhongping Su, Tianhua Xu, Yaqing Wang...
https://pubmed.ncbi.nlm.nih.gov/30957188/Jennifer M Dolan, John Kolega, Hui Meng
https://pubmed.ncbi.nlm.nih.gov/23229281/Suzhou Municipal Hospital
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Collaborating Sponsor